Oral GLP-1 drugs
Oral semaglutide and small-molecule GLP-1 agonists such as orforglipron.
Key point
In adults with obesity or overweight and type 2 diabetes, once-daily orforglipron reduced bodyweight versus placebo, with safety similar to other GLP-1 agonists.
From: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial (Lancet, 2026 Dec 20) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 27, 27, 19, 21, 21.
All papers from the last 12 months
270 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialLancet2026 Dec 20PMID 41275875RCT
- Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertensionAm J Prev Cardiol2026 DecPMID 42830762
- Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signalingBiochem Pharmacol2026 NovPMID 42508653
- Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetesLancet2026 Oct 17PMID 42880294
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trialLancet2026 Oct 17PMID 42815506RCT
- Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 DiabetesPatient2026 Oct 16PMID 42888373
- Obesity: oral therapy for those afraid of needlesExpert Opin Pharmacother2026 Oct 16PMID 42872693Review
- Early Uptake of Oral Semaglutide for Obesity Treatment After Regulatory ApprovalAnn Intern Med2026 Oct 13PMID 42863123
- Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease ModificationDrug Des Devel Ther2026PMID 42871841Review
- Ischemic colitis associated with oral semaglutide with recurrence upon rechallengeRev Esp Enferm Dig2026 Oct 8PMID 42847871
More endocrinology trends
All specialties →Tirzepatide
A dual GIP/GLP-1 receptor agonist for diabetes and obesity.
Next-generation incretin drugs
Triple agonists and amylin combinations such as retatrutide and CagriSema.
Key point: CagriSema led to a greater proportion of adults with obesity achieving BMI and waist-to-height ratio targets than semaglutide, cagrilintide, or placebo.
Automated insulin delivery
Hybrid closed-loop systems that adjust insulin automatically.
Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
orforglipron[tiab] OR "oral semaglutide"[tiab] OR danuglipron[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.